Program
Aurora B/VEGFR/FGFR Inhibitor AL8326
Also written as “AL8326 tablets”, “AL8326 40 mg” and “AL8326 60 mg”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Drug pageAurora B/VEGFR/FGFR Inhibitor AL8326: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Advenchen Laboratories Nanjingits history only | 51 open or running | phase 3since Oct 9, 2023 | Apr 26, 2021 | Jul 2028phase 3 · NCT06247605 |
| Advenchen Laboratoriesits history only | 22 open or running | phase 2since Sep 28, 2025 | Jan 30, 2024 | Dec 2027phase 1 · NCT06794957 |
| Advenchen Pharmaceuticals, LLC. | 11 open or running | phase 2since Apr 22, 2022 | Apr 22, 2022 | Dec 2027phase 2 · NCT05363280 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Advenchen Pharmaceuticals, LLC. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2022First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT05363280 · 80 planned · United States, Spain
Ahead
- Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT05363280
TargetBeta
“An orally bioavailable inhibitor of the receptor kinases Aurora B, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), ”NCIt, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
The one study Advenchen Pharmaceuticals, LLC. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05363280Small Cell Lung Carcinoma · United States, Spain | 2 | Recruiting | Dec 2027 | 80 |
How it is read
Names in the registry
- “AL8326 tablets”, 6 entries
- “AL8326 40 mg”, 1 entry
- “AL8326 60 mg”, 1 entry
- “AL8326 80 mg--stopped”, 1 entry
- “14C-labeled AL8326”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.